Aktiesnakken — December 2009
-
lav cd20
-
arzerra virker bedre ved lavere cd20 fordi vi er effektivere end ritux
-
UNMET medical meet + det kan differentiere ift. rituxian
-
hvornår data?
-
interim analysis?
-
måske interim analysis
-
hvornår hvornår, hun svarede ikke på det
-
I would love to give your more details...tonen er anderledes
-
early stages pipeline
-
2011 kommer der mere i klinikken
-
langt spørgsmål jeg ikke kan høre
-
how will you move the company forward
-
det er behov for flere antistoffer og vi har worldleading skills.
-
penge kan komme fra: arzerra, egfr, salg af fabrik, og udlicensiering af produkter
-
additional financing?
-
hvor går spending og hvilke milestones kan vi vente
-
Mr. Eatwell
-
udgifter for ca. 1 mia....
-
benchmarkdeals for zalut er mellem 50 og 100 mill dollar upfront
-
head to head mellem Zalut og Erbitux måske på vej
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind